Astra Aktiebolag

Fisons Ltd.

Astra Ab

Robert John Murray

Ronald C Griffith

James Edwin MacDonald

William Calvin Shakespeare

Robert James Gentile

Richard J Schmiesing

Michael Balestra

James Russell Matz

John Charles Gordon

James E Macdonald

Donald Mathisen

There are provided compounds of formula (I), ##STR1## wherein D represents a five membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, N or S, optionally substituted at a carbon atom by halogen, trifluoromethyl, alkyl C1 to 6, nitro or cyano, and which is connected to the remainder of the compound of formula (I) through a carbon atom; A represents N(X) or CH(--(CH.sub.2).sub.m --NXY); U represents NH, O or CH.sub.2 ; V represents (CH.sub.2).sub.a ; W represents (CH.sub.2).sub.b ; a, b, m, X and Y are as defined in the specification, together with processes for their preparation and compositions containing them. Compounds of formula (I) are nitric oxide synthetase inhibitors and are useful in therapy.

Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase

There are provided new compounds of formula I: ##STR1## wherein R represents hydrogen or methyl; and n represents 1 or 2; or a pharmaceutically acceptable acid addition salt thereof, together with processes for preparing them, compositions containing them and their use in therapy. Compounds of formula I are expected to be useful in the treatment of psychotic disorders, intellectual impairment disorders and anxiety.

Spiro-azabicyclic compounds useful in therapy

The present invention relates to methods and compositions useful for treating and preventing conditions in which inhibition of nitric oxide synthetase is beneficial. These conditions include stroke, schizophrenia, anxiety, and pain.

Amidine derivatives with nitric oxide synthetase activities

Method of treating or reducing the risk of human disease or condition in which the synthesis or oversynthesis of nitric oxide forms a contributory part wherein a therapeutically effective amount of the compound of formula (I) as defined in the specification is administered to a person suffering from or susceptible to such disease or condition.

Guanidine derivatives useful in therapy as inhibitors of nitric oxide

Spiro-Azabicyclic Compounds useful in therapy

Guanidine derivatives useful in therapy

Bicyclic amidine dervatives as inhibitors of nitric oxide synthetase

Compounds of formula (I) ##STR1## in which R.sub.1 is hydrogen, R.sub.2 is hydrogen or C.sub.1-6 alkyl, R.sub.3 and R.sub.4 independently represent one or more radicals selected from hydrogen, NH.sub.2, NO.sub.2, halogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-6 alkyl, X represents S or --CH.dbd.CH-- group and pharmaceutically acceptable salts are NMDA receptor antagonists.

2-phenyl- and 2-thienyl-(2)-piperidine derivatives having

(S)-.alpha.-phenyl-2-pyridineethanamine, and its pharmaceutically acceptable derivatives, are useful in the treatment of neurodegenerative disorders, and exhibit linear pharmacokinetics.

Compounds for the treatment of neurodegenerative disorders

Compounds of the formula I, ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 independently represent hydrogen, alkyl, phenyl or substituted phenyl with the proviso that two of R.sub.1, R.sub.2, R.sub.3 or R.sub.4 are phenyl or substituted phenyl and two of R.sub.1, R.sub.2, R.sub.3 or R.sub.4 are hydrogen or alkyl;

Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives

Compounds of the formula I, ##STR1## in which: R.sub.1 represents hydrogen or C.sub.1-6 alkyl,

Growing community of inventors

Brighton, NY, United States of America

Robert John Murray